LINDSEY GRIST: Open Payments
NPI 1437913381 · HIGH POINT, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 104 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $705 · 2025 $1,847
Food & beverage: $1,847
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $434 |
| Novo Nordisk Inc | 11 | $320 |
| Lilly USA, LLC | 8 | $191 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $166 |
| Mayne Pharma Commercial LLC | 2 | $145 |
| Corcept Therapeutics | 3 | $101 |
| Kerecis Limited | 1 | $83 |
| GlaxoSmithKline, LLC. | 4 | $74 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Organon LLC | 3 | $57 |
Products named: XIFAXAN, Wegovy, Ozempic, VRAYLAR, UBRELVY, ZEPBOUND, QULIPTA, BIJUVA.
Industry payments across NC — which companies pay providers there.
